Hairy Cell Leukemia: Preliminary Results with Alpha 2 (r) Interferon

Abstract

Ten patients with hairy cell leukemia are being treated at our institution with a therapeutic schedule of α₂(r) interferon (2 × 10⁶ IU/m² s.c. three times per week). Five patients underwent splenectomy from 4 to 108 months before treatment; nonsplenectomized patients had spleens palpable 6 to 12 cm UCM. According to Quesada's response criteria, at the sixth month of therapy, one patient was considered a complete responder, 8 partial responders and one a minor responder, with no differences between splenectomized and nonsplenectomized patients. In nonsplenectomized patients the spleen returned to normal. Our data confirm that interferon, even at low dosages, is a very effective approach for hairy cell leukemia. No evidence was found to contraindicate such therapy.